Doxorubicin inhibits TGF-β signaling in human lung carcinoma A549 cells

European Journal of Pharmacology

Volumn 590, Issue 1-3, 2008, Pages 67-73

  Filyak, Yevhen ^a   Filyak, Oksana ^a   Souchelnytskyi, Serhiy ^b   Stoika, Rostyslav ^a  

^a INSTITUTE OF CELL BIOLOGY   (Ukraine)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anticancer drugs; DNA damage; Doxorubicin; Human lung cancer A549 cells; Smad protein; TGF (transforming growth factor) beta

Indexed keywords

CAGA PROTEIN; CISPLATIN; DOXORUBICIN; LUCIFERASE; METHOTREXATE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UPREGULATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 48049083321     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.05.030     Document Type: Article

References (36)

1. Arcamone F., Animati F., Cuprunico G., and Lombardi P. New developments in antitumor anthracyclines. Pharmacol. Ther. 76 (1997) 117-124
2. Bartram U., and Speer C. The role of transforming growth factor β in lung development and disease. Chest 125 2 (2004) 754-765
3. Beers M.H., and Berkow W.D. The Merk Manual. 17th edn. (1999)
4. Binaschi M., Capranico G., Dal Bo L., and Zunino F. Relationship between lethal effects and topoisomerase II mediated double-strand DNA breaks produced by anthracyclines with different sequence specificity. Mol. Pharmacol. 51 (1997) 1053-1059
5. Brown K., Pietenpol J., and Moses H. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGFβ signaling. J. Cell. Biochem. 101 (2007) 9-33
6. Ciftci K., Su J., and Trovitch P.B. Growth factors and chemotherapeutic modulation of breast cancer cells. J. Pharm. Pharmacol. 55 8 (2003) 1135-1141
7. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., and Gauthier J. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17 11 (1998) 3091-3100
8. Dennler S., Goumans M., and ten Dijke P. Transforming growth factor β signal transduction. J. Leukoc. Biol. 71 (2002) 731-740
9. Derynck R., and Zhang Y. Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature 425 (2003) 577-584
10. Fedier A., Steiner R., Schwarz V., Lenherr L., Haller U., and Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22 (2003) 1169-1173
11. Fukutchi M., Imamura T., Chiba T., Ebisawa T., Kawabata M., Tanaka K., and Miyazono K. Ligand-dependent degradation of Smad3 by ubiquitin ligase complex of ROC1 and associated proteins. Mol. Biol. Cell 12 (2001) 1431-1443
12. Hartman A., and Ford J. BRCA1 and p53: compensatory roles in DNA repair. J. Mol. Med. 81 (2003) 700-707
13. Kim B.C., Lee H.J., Park S.H., Lee S.R., Karpova T.S., McNally J.G., Felici A., Lee D.K., and Kim S.J. Jab1/CSN5, a component of the COP9 signalosome, regulates transforming growth factor beta signaling by binding to Smad7 and promoting its degradation. Mol. Cell. Biol. 24 6 (2004) 2251-2262
14. Korchynskyi O., Landstom M., Stoika R., Funa K., Heldin C.H., ten Dijke P., and Souchelnytskyi S. Expression of Smad proteins in human colorectal cancer. Int. J. Cancer 82 (1999) 197-202
15. Koutsilieris M., Reyes-Moreno C., Choki I., Sourla A., Doillon C., and Pavlidis N. Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors. Mol. Med. 5 2 (1999) 86-97
16. Liberati N., Moniwa M., Borton A., Davie J., and Wang X. An essential role for Mad homology domain 1 in the association of Smad3 with histon deacetylase activity. J. Biol. Chem. 276 (2001) 22595-22603
17. Massague J., Blain S., and Lo R. TGFβ signaling in growth control, cancer and heritable disorders. Cell 103 (2000) 295-309
18. Moustakas A., Souchelnytskyi S., and Heldin C.H. Smad regulation in TGF-beta signal transduction. J. Cell Sci. 114 (2001) 4359-4369
19. Nakao A., Imamura T., Souchelnytskyi S., Kawabata M., Ishisaki A., Oeda E., Tamaki K., Hanai J., Heldin C.H., Miyazono K., and ten Dijke P. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 16 (1997) 5353-5362
20. Oliver F.J., de la Rubia G., Rolli V., Ruiz-Ruiz M.C., de Murcia G., and Murcia J.M. Importance of poly(ADP-ribose)polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J. Biol. Chem. 273 50 (1998) 33533-33539
21. Park S. Fine tuning and cross-talking of TGFβ-signal by inhibitory Smads. J. Biochem. Mol. Biol. 38 1 (2005) 9-16
22. Reguly T., and Wrana J. In or out? The dynamics of Smad nucleocytoplasmic shuttling. Trends Cell Biol. 13 5 (2003) 216-220
23. Repesh L.A., Drake S.R., Warner M.C., Downing S.W., Jyring R., Seftor E.A., Hendrix M.J., and McCarthy J.B. Adriamycin-induced inhibition of melanoma cell invasion is correlated with decreases in tumor cell motility and increases in focal contact formation. Clin. Exp. Metastasis 11 1 (1993) 91-102
24. Roberts A., and Derynck R. Signaling schemes for TGF-β. Sci STKE 18 113 (2001) 43
25. Saunier E.F., and Akhurst R.J. TGF beta inhibition for cancer therapy. Curr. Cancer Drug Targets 6 7 (2006) 565-578
26. Shi Y., and Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
27. Souchelnytskyi S. Transforming growth factor-β signaling and its role in cancer. Exp. Oncol. 24 (2002) 3-12. http://www.exp-oncology.com.ua/en/archives/9/228.html http://www.exp-oncology.com.ua/en/archives/9/228.html
28. Sugiyama T., and Sadzuka Y. Combination of the anine with Doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma. Clin. Cancer Res. 5 2 (1999) 413-416
29. ten Dijke P., and Hill C. New insights into TGF-β-Smad signaling. Trends Biochem. Sci. 29 5 (2004) 265-273
30. Tsuchida K., Sunada Y., Noji S., Murakami T., Uezumi A., and Nakatani M. Inhibitors of the TGF-beta superfamily and their clinical applications. Mini Rev. Med. Chem. 6 11 (2006) 1255-1261
31. Vaage J., Donovan D., Loftus T., and Working P. Prevention of metastasis from mouse mammary carcinomas with liposomes carrying doxorubicin. Br. J. Cancer 72 5 (1995) 1074-1085
32. Wicks S., Lui S., Abdel-Wahab N., Mason R., and Chantry A. Inactivation of Smad-transforming growth factor β signaling by Ca(2+)-calmodulin-dependent protein kinase II. Mol. Cell. Biol. 20 (2000) 8103-8111
33. Wotton D., Lo R., Lee S., and Massague J.A. Smad transcriptional co-repressor. Cell 97 (1999) 29-39
34. Yagi K., Goto D., Hamamoto T., Takenoshita S., Kato M., and Miyazono K. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J. Biol. Chem. 275 (1999) 8825-8834
35. Yanagisawa K., Osada H., Masuda A., Kondo M., Saito T., Yatabe Y., Takagi K., and Takahashi T. Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-b in human normal lung epithelial cells. Oncogene 17 (1998) 1743-1747
36. Zawel L., Dai J., Buckhaults P., Zhou S., Kinzler K.W., Vogelstein B., and Kern S.E. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1 (1998) 611-617